How do you build a telehealth platforms (Teladoc / Amwell) go-to-market motion in 2027?

Segment and ICP first: who actually signs a telehealth contract

Most failed telehealth go-to-market motions in this category die from an ICP error, not a product error. Founders describe their buyer as "healthcare," which is three unrelated purchasing systems wearing the same trench coat: payers, self-insured employers, and provider organizations. Each has different budget owners, different procurement calendars, different proof requirements, and radically different contract sizes. Pick one before you hire a single rep.

The payer segment (national and regional health plans, Medicare Advantage plans, state Medicaid managed-care organizations) buys on medical-loss-ratio math. The economic buyer is a VP of Clinical Programs or a Chief Medical Officer with a cost-of-care target, and the deal is justified by avoided emergency-department visits, avoided admissions, and star-ratings or HEDIS-quality lift. Cycles run 9–18 months because contracting, network credentialing, and actuarial review all serialize. ACVs land anywhere from roughly $500K to eight figures at the largest plans, but you will not see revenue for two to four quarters after signature because implementation runs through eligibility-file plumbing, member-communication approvals, and a phased population ramp.

The self-insured employer segment (typically 1,000–25,000 employees, plus jumbo employers above that) buys on a benefits calendar. The economic buyer is a VP of Total Rewards or Benefits Director, but the deal is brokered — Mercer, Aon, WTW, Gallagher, and the regional benefits consultants sit between you and the buyer, and they control the RFP shortlist. Cycles run 3–9 months and are calendar-locked: decisions cluster in Q2 and Q3 for a January 1 effective date, which means a deal that slips past roughly September slips a full year. ACV ranges from about $50K to $500K at mid-market, with pricing usually expressed per-employee-per-month. This is the fastest segment to get to first revenue and the easiest place to build reference logos.

The provider segment (health systems, medical groups, FQHCs) buys on capacity, throughput, and increasingly on value-based-contract exposure. The buyer set is a CMO plus a CIO plus service-line leadership, and the gating issue is almost always Epic. If you cannot demonstrate a working integration into their existing EHR workflow — not a portal your clinicians alt-tab into, but orders, notes, and scheduling inside the chart — you will lose to the incumbent or to Epic's own telehealth module regardless of your clinical quality.

Layer a vertical wedge on top of the segment choice. The horizontal urgent-care video visit is a commodity: Teladoc and Amwell have distribution advantages you cannot buy, and MDLive and Included Health are already bundled inside major payer stacks. The defensible entry points are behavioral health, women's and family health, chronic-condition and metabolic management, musculoskeletal, and pediatric behavioral. Each has a distinct clinical protocol, a distinct outcome metric, and a buyer willing to carve out a separate line item. Write your ICP as one sentence with four constraints — segment, size band, vertical wedge, EHR or payer stack — and disqualify anything that misses two of the four.

Firmographic scoring that actually predicts close rate: self-insured (not fully insured), 2,000+ covered lives, an existing point-solution stack of three or more vendors (indicates budget and appetite), a broker you have a relationship with, and a renewal date 6–10 months out. Accounts hitting four of five convert at multiples of accounts hitting two. Build that scoring into routing on day one rather than after your first bad quarter.

The motion that fits: brokered, pilot-led, and integration-gated

Once the segment is fixed, the motion follows almost mechanically. Three distinct motions coexist in a mature telehealth platform company, and confusing them is the most common structural error.

SMB and small-employer motion. Inside sales plus self-serve. An SDR-sourced or inbound lead, a 30-minute virtual demo, a standard contract, and a 30–90 day cycle at roughly $10K–$50K ACV. This motion only works if the product genuinely onboards without a solutions architect. If every deal needs custom eligibility mapping, you do not have an SMB motion — you have a mid-market motion you are underpricing.

Mid-market employer motion. Field or hybrid AE plus a broker relationship. The AE's real job is not the buyer meeting; it is being on the consultant's shortlist before the RFP is written. Budget 30–40% of mid-market marketing spend against broker enablement: consultant-facing one-pagers, actuarial-friendly outcome summaries, and Validation Institute or similar third-party outcome validation, because benefits consultants are professionally allergic to unvalidated savings claims. Cycle 3–9 months, ACV $50K–$500K.

Enterprise payer and health-system motion. Field executive plus clinical leadership plus a named implementation lead in the room from the second meeting. Bring a Chief Medical Officer or VP Clinical to every clinical conversation — a salesperson cannot carry a protocol discussion with a health-plan medical director, and attempting it costs you the deal in one meeting. Cycle 9–18 months, ACV $500K to several million.

The compressor across all three is the 90-day pilot on a defined population, typically one employer or one plan segment of roughly 10,000 members. Structure it tightly or it becomes a free perpetual proof-of-concept:

• Scope: one population, one clinical use case, one integration surface. Not three wedges at once.
• Metrics fixed in writing before kickoff: member activation rate, utilization per thousand members, clinical outcome specific to the wedge (for behavioral health, a validated symptom-severity change; for metabolic, an A1c or weight delta), cost-of-care impact, and member satisfaction.
• A named clinical owner on the customer side who is accountable for the readout.
• A pre-agreed conversion trigger — "if activation exceeds X% and utilization exceeds Y, we execute the full agreement at these pre-negotiated terms." Without that clause, a successful pilot restarts procurement from zero.
• A hard end date. Pilots that drift past 120 days convert at dramatically lower rates because the champion's attention has moved on.

Integration is a gate, not a feature. Sequence it deliberately. Build eligibility-file ingestion and payer-claims connectivity first (that is what makes reporting credible), then a single deep EHR integration in whichever system your beachhead segment concentrates in, then breadth. Attempting four EHR integrations simultaneously with a small engineering team produces four shallow ones, and a shallow integration fails the demo in front of a CIO who has seen a dozen of them.

Unit economics and benchmarks: the numbers that decide the model

Telehealth platform economics differ from standard software because delivered care carries real clinical cost. Model gross margin honestly before you set pricing.

Pricing architecture. Three components, used in combination:

• Per-member-per-month (PMPM) access fee — roughly $0.50 to $20 depending on scope. Bare urgent-care access sits at the low end; a specialty program with a dedicated care team sits at the high end. PMPM is the revenue line investors reward because it is recurring and independent of utilization.
• Per-visit or per-episode fee — roughly $20 to $150 depending on specialty. General medical is cheapest; therapy, psychiatry, and complex specialty consults are dearest.
• Value-based or performance component — a portion of fees at risk against agreed outcomes or guaranteed savings. Payers increasingly demand it, and offering it before you have outcome data is how young companies sign contracts they cannot profitably serve.

The PMPM-versus-per-visit mix determines your entire risk posture. Heavy PMPM with low per-visit fees means you carry utilization risk: a high-engagement employer becomes your worst-margin account. Heavy per-visit means revenue swings with engagement, and a low-utilization quarter blows the forecast. Most durable structures use a modest PMPM to cover platform and care-team readiness plus a per-visit fee that covers marginal clinical cost with margin on top.

Gross margin. Expect roughly 50–70% for a delivery-heavy telehealth model, versus 75–85% for pure software. The difference is clinician cost. The levers: asynchronous and messaging-first care (far cheaper per encounter than synchronous video), AI-assisted triage and documentation to lift clinician throughput, correct licensure mix so you are not routing routine encounters to physicians when nurse practitioners are appropriate and permitted, and a contractor-versus-employed clinician blend tuned to utilization variability. A company that never gets asynchronous mix above a modest share will struggle to exceed roughly 55% gross margin, which caps how much sales capacity it can fund.

Sales efficiency. Realistic benchmarks in this category: win rates around 14–26% on qualified opportunities, rising materially — often into the mid-thirties — when a structured 90-day pilot ships, because the pilot converts a promise into evidence. Cost per qualified opportunity in the enterprise motion typically runs several thousand to the high teens of thousands of dollars. CAC payback of 12–30 months is normal and acceptable given multi-year contract terms; anything beyond 30 months means either your ACV is too low for the motion you are running or your cycle assumptions are optimistic.

Retention. Net revenue retention of roughly 102–115% is the realistic band. Note what that implies: gross churn in this category is real. Employers switch vendors at renewal, brokers recommend re-bids, and payers consolidate point solutions. Expansion comes from three places — adding covered populations (a second business unit or a dependent tier), adding wedges (behavioral on top of primary), and adding modules such as remote monitoring or care navigation. Model expansion explicitly by source; a plan that assumes NRR above 115% without naming which motion produces it is a plan built on hope.

The metric that gates everything: member activation. A telehealth contract with low member awareness produces low utilization, which produces no outcome data, which produces a non-renewal — and the customer will blame your product. Treat member engagement as a product and marketing function you own, not something the employer's HR team does for you. Budget for it: campaign creative, multi-channel outreach, incentive design, and a dedicated engagement lead by roughly your twentieth hire. Companies that outsource activation to the customer see materially worse renewals than companies that own it.

Common misfires that kill telehealth go-to-market motions

Selling the horizontal video visit. The single most common failure. Founders build a competent general telemedicine product and pitch it against Teladoc and Amwell on features. You lose on distribution, network breadth, and price, and you burn 18 months learning it. Enter through a wedge where you can claim a specific clinical outcome the incumbents report only in aggregate.

Underestimating the provider network build. A fifty-state licensed clinician network with credentialing, malpractice coverage, and accreditation is an 18–36 month build, not a quarter's work. State licensure, credentialing turnaround, and payer enrollment each add latency. Sell only into the states you are actually licensed in, say so plainly on the ICP screen, and treat network coverage as a gating field in the CRM. Selling a national employer when you cover 22 states creates a launch failure that costs you the reference.

Treating reimbursement as stable. Telehealth payment policy has moved repeatedly — coverage parity, payment parity, cross-state licensure flexibility, and originating-site rules all vary by state and payer and have shifted through recent policy cycles. Never build a revenue forecast whose base case assumes a specific reimbursement rule persists. Build the model so the business survives on employer and cash-pay revenue if a favorable payer rule changes, and treat continued parity as upside.

Ignoring the broker channel. In the employer segment, benefits consultants are the distribution layer. A company that runs pure outbound to HR leaders while ignoring the consultants gets excluded from shortlists it never learns existed. Hire a channel lead for brokers before the fifth AE, not after.

Compliance as an afterthought. HIPAA is table stakes; the enterprise procurement bar is higher — a security questionnaire, a documented risk assessment, penetration test results, business-associate agreements, and often a recognized security certification. Every one of those takes months. Starting the certification process when the first enterprise deal reaches legal adds a full quarter to that deal and often loses it.

Pilot sprawl. Running five concurrent unfunded pilots with different metrics burns the implementation team, produces no comparable evidence, and creates five champions who each expect custom work. Cap concurrent pilots at what your implementation capacity can genuinely serve, charge for them where the segment allows, and standardize the metric set so results compound into a benchmark you can sell with.

Insourcing risk. Large payers and the biggest employers increasingly build or acquire virtual-care capability. Any account where the buyer's parent organization owns a competing asset should be scored down at qualification. Compete there on clinical specialization and measured outcomes, never on convenience.

Operating model and cadence: how the machine runs weekly

The operating model has to reconcile a sales calendar, a clinical operations calendar, and a regulatory calendar that do not naturally align.

Hiring sequence. First five: a founder or commercial leader who sells, a clinical leader with real credibility (a practicing or recently practicing clinician — a health-plan medical director will spot a non-clinician immediately), an implementation and solutions lead who owns pilots end to end, a field AE for the beachhead segment, and a partner or broker lead. Only at ten-plus do you add a second and third AE, an SDR, an integration engineer, and a demand-gen marketer. By twenty-five: a VP Sales, a VP Customer Success, three to five solutions architects, a member-engagement lead, a RevOps analyst, a compliance owner, and clinical operations management scaled to utilization.

Channel mix at steady state. Roughly a quarter of pipeline from inbound and content — healthcare trade press, benefits-focused publications, review sites, and search demand around category comparisons and alternatives. Roughly a third from partner and channel: brokers, EHR marketplaces, cloud healthcare programs, and payer or health-system partnerships. Roughly a third from targeted outbound into named accounts. The remainder from conferences — the major healthcare IT and health-innovation shows plus payer and telehealth association events, which matter disproportionately in this category because buyers use them to compress vendor evaluation into three days.

Cadence specifics. Daily: platform uptime, clinical encounter queue depth and wait times, and integration error rates — a broken eligibility feed silently zeroes activation for an entire account. Weekly: pipeline by segment, every active pilot with days-elapsed and metric status, and member activation by account with anything trending below target flagged for intervention. Monthly: cohort NRR, gross margin by account (find the high-utilization low-PMPM accounts before renewal), and wedge attach rate. Quarterly: enterprise business reviews, expansion planning against the named-population map, and a formal regulatory review — state licensure changes, payment-policy shifts, and payer coverage updates should be a standing agenda item owned by a named person, not a thing someone reads about in a newsletter.

Forecast discipline. Because employer deals are calendar-locked, build the forecast around effective dates rather than close dates, and mark any deal without a confirmed effective date as unforecastable. Because payer deals implement slowly, separate booked ACV from recognized revenue in every board reporting pack. Conflating the two is how telehealth companies surprise their own boards two quarters after a great-looking sales year.

Related questions

Should we sell to employers or payers first?

Employers, in most cases. Cycles are 3–9 months versus 9–18, brokers give you a repeatable distribution channel, and you generate outcome data faster. Payers pay more but demand evidence you will not have until employer cohorts mature.

How many EHR integrations do we need before selling to health systems?

One deep integration in the system your beachhead concentrates in beats four shallow ones. CIOs test depth — orders, notes, scheduling in-workflow — not logo count. Add breadth only after the first integration survives production use.

What outcome metric convinces a benefits consultant?

A validated, wedge-specific clinical measure plus a defensible cost figure, ideally reviewed by a recognized third-party validator. Raw savings claims without methodology are discounted to zero by experienced consultants.

Can we run a product-led motion in telehealth?

Only for cash-pay direct-to-consumer or very small employers. Anything requiring eligibility files, network credentialing, or EHR integration cannot self-serve, and pretending otherwise underprices a high-touch motion.

How do we price against a much larger incumbent?

Not on PMPM. Price your wedge as an additive line item with a specific outcome guarantee. Competing on the incumbent's access-fee axis invites a price war you cannot win.

FAQ

How long should a telehealth pilot run?

Ninety days on one defined population of roughly 10,000 members. Shorter windows do not generate enough utilization to show a clinical signal; longer windows lose champion attention and let the pilot become a permanent free tier. Fix the metrics and the conversion trigger in writing before kickoff.

What gross margin should we plan for?

Roughly 50–70%, depending on how much care is delivered asynchronously and how well your licensure mix matches encounter acuity. Do not model software-like margins of 80%+ unless you are licensing pure technology with no clinical delivery attached.

Who is the real economic buyer?

It varies by segment: a benefits or total-rewards leader at employers, a clinical-programs or medical leader with a cost-of-care target at payers, and a CMO paired with a CIO at provider organizations. In every case a compliance or security owner holds veto power without holding budget.

What is a realistic net revenue retention target?

102–115%. Expansion comes from added populations, added clinical wedges, and added modules. Gross churn is genuinely present in this category because employers re-bid at renewal, so plan retention motions around the renewal calendar rather than assuming stickiness.

How much of the budget should go to member engagement?

Enough to own it as a function rather than delegate it to the customer. Activation drives utilization, utilization drives outcome data, and outcome data drives renewal — so underfunding engagement quietly destroys retention while looking like a marketing line-item saving.

Do we need value-based contracting to compete?

Increasingly with payers, rarely with mid-market employers. Do not offer risk-bearing terms before you have enough cohort data to price the risk; a mispriced guarantee on an early contract can consume the margin from several profitable accounts.

Sources

• https://www.cms.gov/medicare/coverage/telehealth
• https://www.ama-assn.org/practice-management/digital-health
• https://www.kff.org/health-reform/
• https://www.hhs.gov/hipaa/for-professionals/index.html
• https://telehealth.hhs.gov/
• https://www.ncqa.org/
• https://www.himss.org/
• https://www.americantelemed.org/
• https://investors.teladochealth.com/
• https://investors.amwell.com/

Related on PULSE

• [How do you build a mental health and behavioral health platforms (Lyra / Spring Health) go-to-market motion in 2027?](/knowledge/gp0110)
• [How do you build a population health platforms (Arcadia / Innovaccer) go-to-market motion in 2027?](/knowledge/gp0114)
• [How do you build a biotech research platforms (Benchling / Schrödinger) go-to-market motion in 2027?](/knowledge/gp0118)
• [How do you build an AI voice platforms (Vapi / Retell AI) go-to-market motion in 2027?](/knowledge/gp0102)
• [How do you build an iPaaS / integration platforms (Workato / Tray.io / Boomi) go-to-market motion in 2027?](/knowledge/gp0094)